ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2071

The Prevalence of 78 Autoimmune Diseases in Catalonia (MASCAT-PADRIS Big Data Project)

Soledad Retamozo1, Antoni Sisó-Almirall 2, Belchin Kostov 3, Elisenda Martínez-Carbonell 4, Pilar Brito-Zerón 5, Pere Blanch Ramirez 6, Nihan Acar-Denizli 7, Pedro Delicado 6, Susana González-Martínez 8, César Velasco Muñoz 4, Jaume Benavent Àreu 9 and Manuel Ramos-Casals 10, 1Instituto De Investigaciones En Ciencias De La Salud, Univ. Nacional de Córdoba, Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto Universitario de Ciencias Biomédicas de Córdoba, Córdoba, Argentina., Cordoba, Argentina, 2Primary Healthcare Transversal Research Group, Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Primary Care Centre Les Corts, Consorci d’Atenció Primària de Salut Barcelona Esquerra (CAPSBE). Faculty of Medicine, Universitat de Barcelona, Barcelona, Spain., Barcelona, Spain, 3Primary Healthcare Transversal Research Group, Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS). Primary Care Centre Les Corts, Consorci d’Atenció Primària de Salut Barcelona Esquerra (CAPSBE). Department of Statistics and Operations Research, Universitat Politècnica de Catalunya, Barcelona, Spain., Barcelona, Spain, 4Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQUAS), Barcelona, Spain., Barcelona, Spain, 5Sjögren Syndrome Research Group (AGAUR), Laboratory of Autoimmune Diseases Josep Font, IDIBAPS-CELLEX, Department of Autoimmune Diseases, ICMiD, University of Barcelona, Hospital Clínic. Autoimmune Diseases Unit, Department of Medicine, Hospital CIMA- Sanitas, Barcelona, Spain., Barcelona, Spain, 6Department of Statistics and Operations Research, Universitat Politècnica de Catalunya, Barcelona, Spain., Barcelona, Spain, 7Department of Statistics, Faculty of Science and Letters, Mimar Sinan Fine Arts University, Istanbul, Turkey., Istanbul, Turkey, 8Primary Care Centre Les Corts, Consorci d’Atenció Primària de Salut Barcelona Esquerra (CAPSBE), Barcelona, Spain., Barcelona, Spain, 9Primary Healthcare Transversal Research Group, Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS). Primary Care Centre Les Corts, Consorci d’Atenció Primària de Salut Barcelona Esquerra (CAPSBE), Barcelona, Spain., Barcelona, Spain, 10Department of Autoimmune Diseases, ICMiD. Sjögren Syndrome Research Group (AGAUR), Laboratory of Autoimmune Diseases Josep Font, IDIBAPS-CELLEX. Department of Medicine, University of Barcelona, Hospital Clínic, Barcelona, Spain., Barcelona, Spain

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: autoimmune diseases and phenotype, Big data

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, November 12, 2019

Title: Epidemiology & Public Health Poster III: OA, Gout, & Other Diseases

Session Type: Poster Session (Tuesday)

Session Time: 9:00AM-11:00AM

Background/Purpose: To analyze the prevalence of autoimmune diseases (ADs) in Catalonia, a Mediterranean region with nearly 8 million inhabitants using a public administrative big data program.

Methods: The MASCAT-PADRIS Project was designed in 2017 to take a “high-definition” picture of ADs in Catalonia. Individuals with ≥ 1 ICD-9-CM code for an AD recorded during the study period (January 1st, 2012 – December 31st, 2017) to be included. The prevalence rates were estimated for the main subgroups of ADs after grouping the 234 ICD-9-CM ADs codes into a 3-level taxonomy classification that included 78 individual diseases (Level 3), 28 AD subgroups (Level 2) and 10 main AD groups (Level 1) (Figure 1). We assumed that a patient with an AD will visit a primary care center and/or hospital at least once during the 6-year study period. Therefore, the lifetime prevalence for each individual AD was estimated as the number of individuals with ≥ 1 ICD-9-CM code during the study period divided by the mean number of people with public health coverage in Catalonia during the study period and expressed per 100,000 inhabitants.

Results: A total of 799,003 individuals had a diagnosis of AD during the 2012-2017 study period, representing a prevalence of 10.61%. Among the main individual ADs, 25 (32%) were classified as non-rare diseases (prevalence >5/10,000 inhabitants), 26 (33%) as rare diseases (prevalence 1-5/10,000 inhabitants) and the remaining 27 (35%) as very rare diseases (prevalence < 1/10,000 inhabitants). The 10 main individual ADs with the highest prevalence rates were thyroiditis (4.83%), psoriasis (1.64%), type I diabetes mellitus (1.90%), rheumatoid arthritis (0.58%), polymyalgia rheumatica (0.40%), ulcerative colitis (0.33%), lichen planus (0.31%), celiac disease (0.31%), glomerulonephritis (0.29%) and Sjögren syndrome (0.26%) (Figure 2). Of the 799,003 Catalans with ADs, 531,064 (66.46%) were women, with a female:male ratio of 2:1; only 20 (16 were rare diseases) out of the 78 main ADs (26%) were more frequently reported in men. The ADs most frequently reported in woman were Sjögren syndrome (ratio 6:1) biliary cirrhosis (ratio 5.5) and systemic lupus erythematosus (ratio 4.8:1), while ankylosing spondylitis (ratio 1.7:1), type I diabetes mellitus (1.3:1) and psoriasis (1.3:1) were more frequently reported in men. With respect to the country of birth, a south-to-north gradient of higher frequencies was found. For the main individual ADs, some countries had at least three ADs with a higher prevalence than native-born Catalans (India, Pakistan, Paraguay, Honduras, Morocco and the UK). Some ADs showed a geographically-driven higher prevalence: inflammatory bowel disease and multiple sclerosis in European countries, sarcoidosis in India, Pakistan, Morocco and Paraguay, vitiligo in India, Pakistan, Morocco and all Latin American countries, and thyroiditis in India, Honduras and Argentina (Figure 3).

Conclusion: Autoimmune diseases, although sharing a common etiopathogenic basis, are characterized by wide individual heterogeneity in their frequency, organ-specific phenotype, gender ratio, age predominance and ethnic influence.


Disclosure: S. Retamozo, None; A. Sisó-Almirall, None; B. Kostov, None; E. Martínez-Carbonell, None; P. Brito-Zerón, None; P. Blanch Ramirez, None; N. Acar-Denizli, None; P. Delicado, None; S. González-Martínez, None; C. Velasco Muñoz, None; J. Benavent Àreu, None; M. Ramos-Casals, None.

To cite this abstract in AMA style:

Retamozo S, Sisó-Almirall A, Kostov B, Martínez-Carbonell E, Brito-Zerón P, Blanch Ramirez P, Acar-Denizli N, Delicado P, González-Martínez S, Velasco Muñoz C, Benavent Àreu J, Ramos-Casals M. The Prevalence of 78 Autoimmune Diseases in Catalonia (MASCAT-PADRIS Big Data Project) [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/the-prevalence-of-78-autoimmune-diseases-in-catalonia-mascat-padris-big-data-project/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/the-prevalence-of-78-autoimmune-diseases-in-catalonia-mascat-padris-big-data-project/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology